Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more
Defence Therapeutics Inc (DTCFF) - Total Assets
Latest total assets as of September 2025: $2.77 Million USD
Based on the latest financial reports, Defence Therapeutics Inc (DTCFF) holds total assets worth $2.77 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Defence Therapeutics Inc - Total Assets Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Defence Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (June 2024)
Defence Therapeutics Inc's total assets of $2.77 Million consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.8% |
| Accounts Receivable | $96.52K | 20.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Defence Therapeutics Inc's current assets represent 44.8% of total assets in 2024, a decrease from 97.6% in 2020.
- Cash Position: Cash and equivalents constituted 11.8% of total assets in 2024, down from 97.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 20.2% of total assets.
Defence Therapeutics Inc Competitors by Total Assets
Key competitors of Defence Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Defence Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Defence Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Defence Therapeutics Inc is currently not profitable relative to its asset base.
Defence Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.04 | 47.08 |
| Quick Ratio | 0.93 | 0.04 | 47.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-186.94K | $ -4.35 Million | $ 2.37 Million |
Defence Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Defence Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 91.11 |
| Latest Market Cap to Assets Ratio | 46.97 |
| Asset Growth Rate (YoY) | -86.5% |
| Total Assets | $477.75K |
| Market Capitalization | $22.44 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Defence Therapeutics Inc's assets at a significant premium ( 46.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Defence Therapeutics Inc's assets decreased by 86.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Defence Therapeutics Inc (2020–2024)
The table below shows the annual total assets of Defence Therapeutics Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $477.75K | -86.48% |
| 2023-06-30 | $3.53 Million | +390.88% |
| 2022-06-30 | $719.67K | -87.17% |
| 2021-06-30 | $5.61 Million | +193.38% |
| 2020-06-30 | $1.91 Million | -- |